Corticosteroid-responsive cryptogenic chronic hepatitis: Evidence for seronegative autoimmune hepatitis

Daniel J. Gassert, Heriberto Garcia, Kathryn E. Tanaka, John F. Reinus

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Cryptogenic chronic hepatitis (CCH) is diagnosed in patients with persistently elevated aminotransferase levels of unknown etiology. The workup of CCH patients must include a liver biopsy in order to exclude the largely unrecognized diagnosis of seronegative autoimmune hepatitis (SAIH). Patients with SAIH have demographic, biochemical, and histologic features of autoimmune hepatitis (AIH) and may be treated effectively with corticosteroids. Recognition and treatment of SAIH are necessary to prevent progression to end-stage liver disease. We performed a retrospective review of a database of 3507 patients seen at our institution over a 5-year period. Thirty patients with conventional AIH and an additional six patients with SAIH were identified. The two groups were similar with respect to mean age, gender, and baseline biochemistries. Of the 20 AIH patients who had pretreatment liver biopsies, 85% had moderate to severe interface hepatitis, compared to 83.3% of patients with SAIH. In the SAIH group, 83.3% had advanced fibrosis (stage 3 or 4), versus 40% in the conventional AIH group (P = 0.16). All patients were treated with corticosteroids followed by azathioprine. The mean time to remission (normal ALT) was similar in both groups, 2.6 vs. 2.7 months. Within 3 months, 88.9% of AIH patients and 66.7% of SAIH patients were in remission. We conclude that a trial of corticosteroids is a reasonable therapeutic measure in patients with chronic hepatitis that has features of AIH despite negative autoantibody markers. In most patients, clinical remission will be seen within 3 months, possibly avoiding progression to end-stage liver disease.

Original languageEnglish (US)
Pages (from-to)2433-2437
Number of pages5
JournalDigestive Diseases and Sciences
Volume52
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Autoimmune Hepatitis
Chronic Hepatitis
Adrenal Cortex Hormones
End Stage Liver Disease
Biopsy
Liver
Azathioprine
Transaminases
Biochemistry
Autoantibodies
Hepatitis

Keywords

  • Autoantibodies
  • Autoimmune hepatitis
  • Corticosteroid therapy
  • Cryptogenic chronic hepatitis
  • Seronegative autoimmune hepatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Corticosteroid-responsive cryptogenic chronic hepatitis : Evidence for seronegative autoimmune hepatitis. / Gassert, Daniel J.; Garcia, Heriberto; Tanaka, Kathryn E.; Reinus, John F.

In: Digestive Diseases and Sciences, Vol. 52, No. 9, 09.2007, p. 2433-2437.

Research output: Contribution to journalArticle

Gassert, Daniel J. ; Garcia, Heriberto ; Tanaka, Kathryn E. ; Reinus, John F. / Corticosteroid-responsive cryptogenic chronic hepatitis : Evidence for seronegative autoimmune hepatitis. In: Digestive Diseases and Sciences. 2007 ; Vol. 52, No. 9. pp. 2433-2437.
@article{11b56c8c82114485a582ade0c6e68834,
title = "Corticosteroid-responsive cryptogenic chronic hepatitis: Evidence for seronegative autoimmune hepatitis",
abstract = "Cryptogenic chronic hepatitis (CCH) is diagnosed in patients with persistently elevated aminotransferase levels of unknown etiology. The workup of CCH patients must include a liver biopsy in order to exclude the largely unrecognized diagnosis of seronegative autoimmune hepatitis (SAIH). Patients with SAIH have demographic, biochemical, and histologic features of autoimmune hepatitis (AIH) and may be treated effectively with corticosteroids. Recognition and treatment of SAIH are necessary to prevent progression to end-stage liver disease. We performed a retrospective review of a database of 3507 patients seen at our institution over a 5-year period. Thirty patients with conventional AIH and an additional six patients with SAIH were identified. The two groups were similar with respect to mean age, gender, and baseline biochemistries. Of the 20 AIH patients who had pretreatment liver biopsies, 85{\%} had moderate to severe interface hepatitis, compared to 83.3{\%} of patients with SAIH. In the SAIH group, 83.3{\%} had advanced fibrosis (stage 3 or 4), versus 40{\%} in the conventional AIH group (P = 0.16). All patients were treated with corticosteroids followed by azathioprine. The mean time to remission (normal ALT) was similar in both groups, 2.6 vs. 2.7 months. Within 3 months, 88.9{\%} of AIH patients and 66.7{\%} of SAIH patients were in remission. We conclude that a trial of corticosteroids is a reasonable therapeutic measure in patients with chronic hepatitis that has features of AIH despite negative autoantibody markers. In most patients, clinical remission will be seen within 3 months, possibly avoiding progression to end-stage liver disease.",
keywords = "Autoantibodies, Autoimmune hepatitis, Corticosteroid therapy, Cryptogenic chronic hepatitis, Seronegative autoimmune hepatitis",
author = "Gassert, {Daniel J.} and Heriberto Garcia and Tanaka, {Kathryn E.} and Reinus, {John F.}",
year = "2007",
month = "9",
doi = "10.1007/s10620-006-9665-4",
language = "English (US)",
volume = "52",
pages = "2433--2437",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "9",

}

TY - JOUR

T1 - Corticosteroid-responsive cryptogenic chronic hepatitis

T2 - Evidence for seronegative autoimmune hepatitis

AU - Gassert, Daniel J.

AU - Garcia, Heriberto

AU - Tanaka, Kathryn E.

AU - Reinus, John F.

PY - 2007/9

Y1 - 2007/9

N2 - Cryptogenic chronic hepatitis (CCH) is diagnosed in patients with persistently elevated aminotransferase levels of unknown etiology. The workup of CCH patients must include a liver biopsy in order to exclude the largely unrecognized diagnosis of seronegative autoimmune hepatitis (SAIH). Patients with SAIH have demographic, biochemical, and histologic features of autoimmune hepatitis (AIH) and may be treated effectively with corticosteroids. Recognition and treatment of SAIH are necessary to prevent progression to end-stage liver disease. We performed a retrospective review of a database of 3507 patients seen at our institution over a 5-year period. Thirty patients with conventional AIH and an additional six patients with SAIH were identified. The two groups were similar with respect to mean age, gender, and baseline biochemistries. Of the 20 AIH patients who had pretreatment liver biopsies, 85% had moderate to severe interface hepatitis, compared to 83.3% of patients with SAIH. In the SAIH group, 83.3% had advanced fibrosis (stage 3 or 4), versus 40% in the conventional AIH group (P = 0.16). All patients were treated with corticosteroids followed by azathioprine. The mean time to remission (normal ALT) was similar in both groups, 2.6 vs. 2.7 months. Within 3 months, 88.9% of AIH patients and 66.7% of SAIH patients were in remission. We conclude that a trial of corticosteroids is a reasonable therapeutic measure in patients with chronic hepatitis that has features of AIH despite negative autoantibody markers. In most patients, clinical remission will be seen within 3 months, possibly avoiding progression to end-stage liver disease.

AB - Cryptogenic chronic hepatitis (CCH) is diagnosed in patients with persistently elevated aminotransferase levels of unknown etiology. The workup of CCH patients must include a liver biopsy in order to exclude the largely unrecognized diagnosis of seronegative autoimmune hepatitis (SAIH). Patients with SAIH have demographic, biochemical, and histologic features of autoimmune hepatitis (AIH) and may be treated effectively with corticosteroids. Recognition and treatment of SAIH are necessary to prevent progression to end-stage liver disease. We performed a retrospective review of a database of 3507 patients seen at our institution over a 5-year period. Thirty patients with conventional AIH and an additional six patients with SAIH were identified. The two groups were similar with respect to mean age, gender, and baseline biochemistries. Of the 20 AIH patients who had pretreatment liver biopsies, 85% had moderate to severe interface hepatitis, compared to 83.3% of patients with SAIH. In the SAIH group, 83.3% had advanced fibrosis (stage 3 or 4), versus 40% in the conventional AIH group (P = 0.16). All patients were treated with corticosteroids followed by azathioprine. The mean time to remission (normal ALT) was similar in both groups, 2.6 vs. 2.7 months. Within 3 months, 88.9% of AIH patients and 66.7% of SAIH patients were in remission. We conclude that a trial of corticosteroids is a reasonable therapeutic measure in patients with chronic hepatitis that has features of AIH despite negative autoantibody markers. In most patients, clinical remission will be seen within 3 months, possibly avoiding progression to end-stage liver disease.

KW - Autoantibodies

KW - Autoimmune hepatitis

KW - Corticosteroid therapy

KW - Cryptogenic chronic hepatitis

KW - Seronegative autoimmune hepatitis

UR - http://www.scopus.com/inward/record.url?scp=34547839690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547839690&partnerID=8YFLogxK

U2 - 10.1007/s10620-006-9665-4

DO - 10.1007/s10620-006-9665-4

M3 - Article

C2 - 17429719

AN - SCOPUS:34547839690

VL - 52

SP - 2433

EP - 2437

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 9

ER -